Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.
Also called NCT01541189
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT01541189
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01541189. Allocation not applicable; no masking; primary purpose treatment. Start 2012-02 (registry gives no type); primary completion 2013-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.
- Condition
- Hypertension
- Intervention (Drug)
- Valsartan
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01541189- Content hash
6b64b3d0759e076a3cd5fc8abb5f0340078c7072e15754638238e2baa0bfc040